BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for...(ryst has finalized its plans for Phase 3...),Health

Date:9/21/2009

ryst has finalized its plans for Phase 3 studies intended to support U.S. regulatory approval of peramivir for influenza. Expenses for the Phase 3 studies are covered under the modified HHS contract announced today. BioCryst is currently in the process of obtaining the appropriate Health Authority and IRB/Ethics Committee approvals and is recruiting investigators for these studies in the U.S. and abroad. BioCryst plans to initiate enrollment of these trials in the upcoming flu season.

Further details regarding these Phase 3 studies are available on the internet at:

http://www.clinicaltrials.gov/ct2/results?term=Peramivir+HHS+Phase+3&recr=Open

About peramivir

Peramivir is an anti-viral agent that was discovered by BioCryst which inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for regulatory approval in Japan this year.

About Influenza

Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. According to the U.S. Centers for Disease Control & Prevention, on average 5 to 20 percent of the population gets the flu in the U.S.; more than 200,000 people are hospitalized from flu complications and about 36,000 people die from flu-related causes.

More informatio
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. BioCryst to Present at UBS Global Life Sciences Conference
2. BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
3. BioCryst Executives to Present at Two Investor Conferences
4. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
5. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
6. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
7. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
8. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
9. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007